Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.
about
Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis unitsSolvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye SyndromeDevelopment of an HIV-1 Subtype Panel in China: Isolation and Characterization of 30 HIV-1 Primary Strains Circulating in ChinaPathogen inactivation technologies for cellular blood components: an updatePilot studies for development of an HIV subtype panel for surveillance of global diversity.Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2.Transfusion-transmitted human immunodeficiency virus (HIV) from seroconverting donors is rare in England and Wales: results from HIV lookback, October 1995 through December 2008.Quality and Safety in Blood Supply in 2010Screening acute HIV infections among Chinese men who have sex with men from voluntary counseling & testing centers.Screening Donated Blood for Transfusion Transmitted Infections by Serology along with NAT and Response Rate to Notification of Reactive Results: An Indian Experience.Occult hepatitis B virus infection among blood donors in ColombiaInterpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits'Sterility Testing of Blood Components and Advanced Therapy Medicinal Products' (Munich, April 29, 2010) Organized by the DGTI Section 'Safety in Hemotherapy' - Meeting ReportEvaluation of Risk Minimisation Measures for Blood Components - Based on Reporting Rates of Transfusion-Transmitted Reactions (1997-2013).Molecular virology in transfusion medicine laboratory.Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infectionImplementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.Human Immunodeficiency Virus (HIV).Comment on: One window-period donation in two years of individual donor-nucleic acid test screening for hepatitis B, hepatitis C and human immunodeficiency virus.Factors in enhancing blood safety by nucleic acid technology testing for human immunodeficiency virus, hepatitis C virus and hepatitis B virus.Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.Transmission of human immunodeficiency virus Type-1 by fresh-frozen plasma treated with methylene blue and light.[Human immunodeficiency virus: position of Blood Working Group of the Federal Ministry of Health].Quarantine Plasma: Quo vadis?Inclusion of human immunodeficiency virus Type 2 (HIV-2) in a multiplex transcription-mediated amplification assay does not affect detection of HIV-1 and hepatitis B and C virus genotypes: a multicenter performance evaluation study.Half a decade of mini-pool nucleic acid testing: Cost-effective way for improving blood safety in India.Where now for transfusion: the evolution of a paradigm and its logical progression.Detection and identification of occult HBV in blood donors in Taiwan using a commercial, multiplex, multi-dye nucleic acid amplification technology screening test.NAT yield for human immunodeficiency and hepatitis C viruses in Brazilian blood donors: preliminary results.Blood screening nucleic acid amplification tests for human immunodeficiency virus Type 1 may require two different amplification targets.
P2860
Q24243600-67AF0368-DADF-4649-9B4B-64C3F7DF3625Q24282614-878B682C-66D8-45D3-B19C-7D806F795D5AQ28547519-457B4985-45C3-44F1-80C3-22C7C0B7E718Q28655769-7A8C952E-BD54-47FC-BD91-BEBCDFDFC093Q30514155-4D917CD1-CB0F-4782-9534-582B04D948A0Q33455459-C7300ABB-6852-4F26-B80F-B1A3AD2DE63CQ33777205-86BF9E25-ED41-4471-B6BF-97093DE7D07FQ33929726-536FF803-CE7E-480A-AA36-ACADA3534F41Q34110368-27428875-7A33-480A-A537-1A72DD1B8471Q34591447-2668137C-0E51-4761-A44D-3B1380AEFDF8Q34636134-2C0A0C44-4735-41DF-BD1F-056AB857EE5CQ34741602-2B381194-05C9-4BBB-AAFE-0D34A24FB1A4Q35998371-FA9EAB79-7718-4F36-9B28-C42F4476570AQ36058263-4BAA9DF9-2C8F-4F1B-B87E-6BF92F877FD0Q36766449-FEB7A4F6-1D1A-46B5-B3AF-A1AABDE04D6AQ36766479-FD0DFA16-156F-4BAA-B272-4ACA9CBF54A6Q37045800-2519620B-8513-424F-A91D-F08AD3EF7310Q37045832-70F73B38-20B5-4645-BA59-0D72346DA4D5Q37212572-B9EA5B45-2649-4290-B89D-FF7ACD2E0AE3Q37618604-12332DC1-EC6D-4BB9-A723-ABBEE951AD53Q37630304-845FDCA1-C042-472B-812E-A4A4A59E99F2Q40903377-670C6DC3-0ACC-47C0-8F97-3388E5405903Q40942917-4E526FF5-17A9-4B28-B60B-22016C990911Q41269653-6FF45C79-996C-4978-A3C8-9DB91C24DED8Q41647666-DA714B72-FEFB-406A-B092-CC9E9FFB918BQ42000353-C9D913F7-AD31-4BBF-BF19-92658E061835Q42111649-95AA21D6-43DB-4264-8720-101415DE3C05Q42279560-ED393136-B0AB-4478-9609-E1917FB60725Q43047121-9100F5CB-6B65-4402-8611-742AEF7A9673Q45364475-734D2F79-AD21-48E2-B5CD-82B23374D9E7
P2860
Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Experience of mandatory nuclei ...... us breakthrough transmissions.
@en
Experience of mandatory nucleic acid test
@nl
type
label
Experience of mandatory nuclei ...... us breakthrough transmissions.
@en
Experience of mandatory nucleic acid test
@nl
prefLabel
Experience of mandatory nuclei ...... us breakthrough transmissions.
@en
Experience of mandatory nucleic acid test
@nl
P2093
P2860
P1433
P1476
Experience of mandatory nuclei ...... us breakthrough transmissions.
@en
P2093
Brigitte Keller-Stanislawski
C Micha Nübling
Julia Kress
Margarethe Heiden
Markus B Funk
Michael Chudy
Rainer Seitz
P2860
P304
P356
10.1111/J.1537-2995.2009.02212.X
P577
2009-05-14T00:00:00Z